MA28815B1 - Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda - Google Patents

Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda

Info

Publication number
MA28815B1
MA28815B1 MA29702A MA29702A MA28815B1 MA 28815 B1 MA28815 B1 MA 28815B1 MA 29702 A MA29702 A MA 29702A MA 29702 A MA29702 A MA 29702A MA 28815 B1 MA28815 B1 MA 28815B1
Authority
MA
Morocco
Prior art keywords
indole
antagonists
nmda receptor
carboxamidine derivatives
carboxamidine
Prior art date
Application number
MA29702A
Other languages
English (en)
Inventor
Istvan Borza
Csilla Horvath
Sandor Farkas
Jozsef Nagy
Sandor Kolok
Original Assignee
Richter Gedeon Vegyeszet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Vegyeszet filed Critical Richter Gedeon Vegyeszet
Publication of MA28815B1 publication Critical patent/MA28815B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
MA29702A 2004-07-29 2007-02-22 Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda MA28815B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0401523A HUP0401523A3 (en) 2004-07-29 2004-07-29 Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them

Publications (1)

Publication Number Publication Date
MA28815B1 true MA28815B1 (fr) 2007-08-01

Family

ID=89985408

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29702A MA28815B1 (fr) 2004-07-29 2007-02-22 Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda

Country Status (21)

Country Link
US (1) US20090048303A1 (fr)
EP (1) EP1773770B1 (fr)
JP (1) JP2008508248A (fr)
KR (1) KR20070038502A (fr)
CN (1) CN1989103A (fr)
AP (1) AP2006003840A0 (fr)
AT (1) ATE427299T1 (fr)
AU (1) AU2005266160A1 (fr)
BR (1) BRPI0513932A (fr)
CA (1) CA2574155A1 (fr)
DE (1) DE602005013675D1 (fr)
EA (1) EA009981B1 (fr)
GE (1) GEP20094606B (fr)
HU (1) HUP0401523A3 (fr)
IL (1) IL179485A0 (fr)
MA (1) MA28815B1 (fr)
MX (1) MX2007001052A (fr)
NO (1) NO20071109L (fr)
TN (1) TNSN07016A1 (fr)
WO (1) WO2006010965A1 (fr)
ZA (1) ZA200700325B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
WO2008055945A1 (fr) 2006-11-09 2008-05-15 Probiodrug Ag Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (fr) 2007-04-18 2017-01-11 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
EP2475428B1 (fr) 2009-09-11 2015-07-01 Probiodrug AG Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase
SG183111A1 (en) 2010-02-16 2012-09-27 Pfizer (r)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3-yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2h-pyran-4-ol, a partial agonist of 5-ht4 receptors
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (fr) 2010-04-21 2011-10-27 Probiodrug Ag Nouveaux inhibiteurs
EP2640720B1 (fr) * 2010-11-18 2018-10-17 Yale University, Inc. Molécules bifonctionnelles dotées d'une activité de recrutement d'anticorps et d'inhibition de l'entrée du virus dirigées contre le virus de l'immunodéficience humaine
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
JP2015517563A (ja) * 2012-05-22 2015-06-22 アウトイフオンイ トヘラペウトイクス リミテッド Ｋｖ３阻害剤としてのヒダントイン誘導体
JO3579B1 (ar) 2014-09-26 2020-07-05 Luc Therapeutics Inc مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول
EP3660003B1 (fr) 2017-07-28 2024-01-24 Takeda Pharmaceutical Company Limited Composé hétérocyclique
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase
JP2021050161A (ja) 2019-09-25 2021-04-01 武田薬品工業株式会社 複素環化合物及びその用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9726388D0 (en) * 1997-12-12 1998-02-11 Cerebrus Ltd Chemical compounds
US6376530B1 (en) * 1999-05-10 2002-04-23 Merck & Co., Inc. Cyclic amidines useful as NMDA NR2B antagonists
US6319944B1 (en) * 1999-05-10 2001-11-20 Merck & Co., Inc. Aryl amidines, compositions containing such compounds and methods of use
GB0015488D0 (en) * 2000-06-23 2000-08-16 Merck Sharp & Dohme Therapeutic agents
HU227197B1 (en) * 2000-10-24 2010-10-28 Richter Gedeon Nyrt Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them
JP2004253425A (ja) * 2003-02-18 2004-09-09 Tdk Corp 積層コンデンサ

Also Published As

Publication number Publication date
DE602005013675D1 (de) 2009-05-14
HU0401523D0 (en) 2004-09-28
GEP20094606B (en) 2009-02-10
ZA200700325B (en) 2008-05-28
HUP0401523A3 (en) 2007-05-02
AU2005266160A1 (en) 2006-02-02
KR20070038502A (ko) 2007-04-10
WO2006010965A1 (fr) 2006-02-02
US20090048303A1 (en) 2009-02-19
CN1989103A (zh) 2007-06-27
CA2574155A1 (fr) 2006-02-02
IL179485A0 (en) 2007-05-15
EP1773770B1 (fr) 2009-04-01
TNSN07016A1 (en) 2008-06-02
EA200700365A1 (ru) 2007-06-29
NO20071109L (no) 2007-02-27
JP2008508248A (ja) 2008-03-21
HUP0401523A2 (en) 2006-11-28
ATE427299T1 (de) 2009-04-15
AP2006003840A0 (en) 2006-12-31
EA009981B1 (ru) 2008-04-28
EP1773770A1 (fr) 2007-04-18
BRPI0513932A (pt) 2008-05-20
MX2007001052A (es) 2007-04-16

Similar Documents

Publication Publication Date Title
MA28815B1 (fr) Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
DK1904477T3 (da) Indol-3-carbonyl-spiro-piperodom-derivater som V1A-receptorantagonister
FR20C1027I2 (fr) Derives de tiglien-3-one
DK2094690T3 (da) 2-aza-bicyclo[3.1.0]hexanderivater som orexinreceptorantagonister
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DK1711465T3 (da) Hydroisoindolin-tachykinikreceptorantagonister
DK1943242T3 (da) Piperidin-4-yl-pyridazin-3-ylamin-derivater som hurtigt opløsende antagonister af dopamin-2-receptorer
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DK2402005T3 (da) Formuleringer med langvarig frigivelse af nalbuphin
MA28686B1 (fr) Derives de pyrrolopyridine
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
ATE420088T1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4- rezeptoragonisten
DK1928821T3 (da) Carboxamidderivater som muscarinreceptorantagonister
RU2458924C3 (ru) Соединения замещенных диазепанов в качестве антагонистов орексиновых рецепторов
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
IS8117A (is) 3-Flúr-píperidín sem NMDA/NR2B mótlyf
ZA200806065B (en) Oxazoloisoquinoline derivatives as thrombin receptor antagonists
DK1912976T3 (da) Indol-3-YL-carbonyl-piperidin-benzoimidazolderivater som V1A-receptorantagonister
MA28607B1 (fr) Derives d'aminopyridine utiles comme agonistes de dopamine d3 selectifs
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
DK1833821T3 (da) Sulfamider som endotelreceptorantagonister til behandlingen af kardiovaskulære sygdomme
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
DK1627578T3 (da) Beslag til fastgørelse af svingbare foldeben